Cambrex Milan Constructs New $30 Million R&D Facility; Celebrates 80th Anniversary
CDMO Cambrex started construction on a new R&D facility at its Milan, Italy site. The $30 million investment adds advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants.
The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future growth and rising demand for CDMO services, Cambrex also acquired additional land adjacent to the site, ensuring the capacity to expand and innovate for years to come.
The Cambrex Profarmico Milano site, which marks its 80th anniversary this year, supports pharmaceutical development and manufacturing for its global client base.
Claudio Russolo, Chief Operating Officer at Cambrex, commented: “Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in new technologies and capabilities, but in the future of our people and our partners.”
The investment builds on Cambrex’s legacy of scientific expertise and manufacturing excellence while positioning the company for its next chapter of growth. By expanding R&D capabilities in Milan, Cambrex is strengthening its ability to address the increasing complexity of today’s small molecule therapies.
